Evidence-based clinical practice guideline for deprescribing cholinesterase inhibitors and memantine

This guideline from the University of Sydney, the NHMRC Partnership Centre, and Bruyère Research Institute aims to provide guidance on who is suitable to continue and who is suitable to trial deprescribing (likely to benefit or not experience harm from withdrawal) of certain medications (ChEIs and/or memantine).